Active Equity ETFs

Adapting to changing markets while staying focused on investor outcomes

In today’s dynamic markets, the one constant is that the next decade will be different than the last. Passive investing can leave you exposed to missed opportunities and outdated benchmarks.

Why choose Active Equity ETFs?


  • Active stock selection backed by deep fundamental research
  • Growth potential driven by active decision-making
  • Built to adapt as markets, rates, and capital costs evolve

Our Active Equity ETFs


Active ETFs continue to gain momentum, highlighting their growing role in modern portfolios. Here’s a simple view of how our Active Equity ETFs can fit into a portfolio, whether serving as a core foundation or a satellite enhancer.

Filter by: 

 
 

Active Core
Quality-informed, fundamentals-driven strategies with adaptable approaches and risk-mitigation overlays to capture opportunities and manage volatility.

Active Satellite
High-conviction, thematic strategies that go beyond benchmarks to drive high alpha potential with differentiated exposures.

Ticker Name Portfolio positioning Primary exposure
JSMD Active Core Small/mid-cap growth equities
JSML Active Core Small growth equities
JMID Active Core Mid-cap growth equities
JXX Active Satellite Diversified large growth equities
JHAI Active Satellite Companies driven by the transformation in AI
JRE Active Satellite REITs and real estate related businesses

Subscribe to our ETF Insights

Our latest thinking on the themes shaping today's investment landscape

Leverage our ETF specialists


With a deep understanding of exchange-traded funds, our ETF Client Product Specialists can provide strategic guidance on implementation and portfolio construction.

Daniel Aronson, CFA

Managing Director, ETF Client Product Specialist

Craig Dehner

Executive Director, ETF Client Product Specialist

Lee Gross, CFA

Executive Director, ETF Client Product Specialist

Mike Laughlin, CFA, FRM

Executive Director, ETF Client Product Specialist

Jake Kreiter

Associate Director, ETF Client Product Specialist

Differentiated insights


Data center power: Why the key risk is under delivery, not overbuild

Why the prevailing narrative of new energy-generation capacity exceeding AI data center demand could be off the mark.

Pharma and biotech in 2026: A catalyst‑rich year ahead

With innovation back in focus, a dense slate of drug launches, data readouts, and regulatory decisions makes 2026 a consequential year for pharma and biotech.

Market moves & themes that mattered: February 2026

A monthly market update featuring global equity and fixed income performance, sector and asset class trends, and key themes shaping the investment landscape.